Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: A children's oncology group study

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 9, 2007, Pages 627-632

  Wacker, Pierre ^a   Land, Vita J ^b   Camitta, Bruce M ^c,h   Kurtzberg, Joanne ^d   Pullen, Jeanette ^e   Harris, Michael B ^f   Shuster, Jonathan J ^g  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Children's Oncology Group   (United States)

^c Midwest children'S' Cancer Center   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^f HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

^h CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

Acute lymphoblastic leukemia; Allergy; Chemotherapy; L asparaginase

Indexed keywords

ASPARAGINASE; CYTARABINE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLERGIC REACTION; ARTICLE; CAUCASIAN; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERWINIA; ESCHERICHIA COLI; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION;

ADOLESCENT; ADULT; ASPARAGINASE; BACTERIAL PROTEINS; CHILD; CHILD, PRESCHOOL; ERWINIA; ESCHERICHIA COLI; HUMANS; HYPERSENSITIVITY; INFANT; LEUKEMIA, B-CELL, ACUTE; MALE; TREATMENT OUTCOME;

EID: 34548387897     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181483df1     Document Type: Article

References (23)

1. Kidd JG. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. J Exp Med. 1953;98:565-583.
2. Ortega JA, Nesbit ME, Donalson MH, et al. L-asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res. 1977;37:535-540.
3. Ertel IJ, Nesbit ME, Hammond D, et al. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. Cancer Res. 1979;39:3893-3896.
4. Clavell LA, Gelber RD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. New Engl J Med. 1986;315:657-663.
5. Sallan SE, Hitchcock-Bryan S, Gelber R, et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983;43:5601-5607.
6. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13:335-342.
7. Harris MB, Shuster JJ, Pullen J, et al. Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol. 1998;16:2840-2847.
8. Harris MB, Shuster JJ, Pullen J, et al. Treatment of children with early Pre-B and Pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: a Pediatric Oncology Group Study. Leukemia. 2000;14:1570-1576.
9. Nesbit N, Chard R, Evans A, et al. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol. 1979;1:9-13.
10. Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer. 1982;49:1378-1383.
11. Cairo MS. Adverse reactions of L-asparaginase. Am J Pediatr Hematol Oncol. 1982;4:335-339.
12. Feinberg WM, Swenson MR. Cerebrovascular complications of L-asparaginase therapy. Neurology. 1988;38:127-133.
13. Woo MH, Hak LJ, Storm MC, et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia. 1998;12:1527-1533.
14. Avramis VI. Anti-asparaginase (ASNase) antibody (Ab) in pediatric patients in high risk ALL study (CCG-1961): correlation of Ab and clinical allergy. J Clin Oncol. 2000;19:589a.
15. Ohnuma T, Holland JF, Meyer P. Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli. Cancer. 1972;30:376-381.
16. King OJ, Wilbur JR, Mumford DM, et al. Therapy with Erwinia L-asparaginase in children with acute leukemia after anaphylaxis to E. coli L-asparaginase. Cancer. 1974;33:611-614.
17. Billet AL, Carls A, Gelber RD, et al. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer. 1992;70:201-206.
18. Crist WM, Carroll AJ, Shuster JJ, et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood. 1990;76:117-122.
19. Kurtzberg J, Asselin B, Poplack D, et al. Antibodies to asparaginase alter pharmacokinetics and decrease enzyme activity in patients on asparaginase therapy. Proc Am Assoc Cancer Res. 1993;34:304.
20. Asselin BL, Whiting JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993;11:1780-1786.
21. Woo M, Hak L, Storm M, et al. Anti-asparaginase (ASP) antibodies do not impact event-free survival (EFS) in children with acute lymphoblastic leukemia (ALL). J Clin Oncol. 1999;18:567a.
22. Otten J, Suciu S, Lutz P, et al. The importance of L-asparaginase (A'ase) in the treatment of acute lymphoblastic leukemia (ALL) in children: results of the EORTC 58881 randomize phase III trial showing greater efficiency of Escherichia coli (E. coli) as compared to Erwinia (ERW) A'ase. Blood. 1996;88:2663.
23. Larson RA, Fretzin MH, Dodge RK, et al. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia. 1998;12:660-665.